Observational studyBMC infectious diseases2025
High-density lipoprotein 2b combined with sequential organ failure assessment score as a novel prognostic indicator for sepsis patients: a prospective study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Admission lipid profile and outcomes in sepsis requiring early invasive source control.BMC infectious diseases · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSepsis is a state of life-threatening organ dysfunction caused by a dysregulated host response to infection, leading to consecutive organ failure and lethal outcome. The purpose of this study is to assess the value of the combined use of plasma high-density lipoprotein 2b (HDL2b) level and Sequential Organ Failure Assessment (SOFA) score in predicting short-term mortality from sepsis. MATERIALS AND
methodsA prospective, observational study was conducted in patients with sepsis and non-septic controls admitted to three intensive care units (ICUs) from January 2020 to December 2021. SOFA scores were recorded on the first day after admission. Blood samples were collected from each enrolled patient and the levels of HDL2b were analyzed using microfluidic chip technology. Receiver-operator characteristic curve (ROC) analyses were conducted to determine the values of plasma HDL2b level, SOFA score and the combined HDL2b levels and SOFA score (HDL2b + SOFA) in predicting the prognosis of mortality, respectively. The primary endpoint was 28-day mortality and the secondary outcome was total in-hospital mortality.
resultsCompared to non-septic controls, patients with sepsis had lower HDL2b levels (10.95% [8.95, 12.96] vs. 23.78% [14.53, 29.16], p < 0.001). Among sepsis patients, the levels of HDL2b of non-survivors were lower than those of survivors (6.74% [4.63, 8.08] vs. 11.78 [7.20, 13.40], p = 0.002). Moreover, our data also indicated that patients with higher HDL2b + SOFA scores shown higher rates of 28-day and total in-hospital mortality. The areas under the ROC curves for predicting 28-day mortality were 0.755 for HDL2b, 0.782 for SOFA, and 0.806 for HDL2b + SOFA. Multivariate analyses indicated that HDL2b + SOFA (Odd Ratio: 1.321 (95% Confidence Interval: 1.028-1.698), p = 0.029) was potential predictors of 28-day mortality.
conclusionsThe HDL2b + SOFA composite score was a reliable predictor of 28-day and in-hospital mortality in sepsis patients, showing better discriminatory ability than SOFA alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.